Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection

NCT04312997 is registered in ClinicalTrials.gov with Pulmotect, Inc. as lead sponsor.

NCT NCT04312997
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04312997 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multiple Dose Study to Evaluate the Efficacy and Safety of PUL-042 Inhalation Solution in Reducing the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection
Lead sponsor
Pulmotect, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 16, 2020
Completion date
July 2, 2021
Enrollment
101 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19